Conditional Approval and Pricing of New Drugs – Asrar Qureshi’s Blog Post #1313
Conditional Approval and Pricing of New Drugs – Asrar Qureshi’s Blog Post #1313 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1313 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com for publishing your contributions here. Credit: Pavel Danilyuk Preamble This post is based on INSEAD research by Professor Stephen E. Chick. This is a provocative research which answers and raises several questions.Link at the end. The Real Cost of Health Innovation: Who Pays for Life-Saving Breakthroughs? A new medicine can take more than a decade to reach a patient. It may require billions of dollars of investment, years of laboratory research, multiple stages of clinical trials and increasingly complex regulatory scrutiny. Even after demonstrating promising results, however, a new treatment can face another formidable barrier: will a health system actually pay for it and make i...